Maftivimab is a fully human IgG1κ monoclonal antibody that specifically targets the envelope glycoprotein (GP1,2) of the Zaire ebolavirus (EBOV). By binding to the viral glycoprotein with high affinity, it blocks the interaction between the virus and host cell receptors, thereby preventing viral entry. As an IgG1 isotype, it is also designed to engage immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC), potentially contributing to viral clearance. It functions as a neutralizing antibody and is developed as part of a therapeutic or prophylactic strategy against Ebola virus disease (EVD), often evaluated in combination with other monoclonal antibodies in a cocktail regimen.